Ani pharmaceuticals announces approval and launch of aminocaproic acid tablets

Baudette, minn.--(business wire)--ani pharmaceuticals, inc. (“ani” or the “company”) (nasdaq: anip) today announced u.s. food and drug administration (fda) approval and the launch of aminocaproic acid tablets usp, 500mg. the current annual u.s. market for this product is approximately $12.7 million, according to iqvia/ims health. "this is ani's seventh generic product launch in 2020 and reaffirms our commitment to increasing the pace of market introductions for our products. this important ther
ANIP Ratings Summary
ANIP Quant Ranking